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Objective In 2002–03, the Republic of the Congo increased the threshold separating stage 1 and 2 cases of human African 
trypanosomiasis (HAT) from a cerebrospinal fluid (CSF) white cell count of 5 cells/mm³ to 10 cells/mm³. We aimed to assess whether 
the increased threshold of 10 cells/mm³ is a safe indicator of stage 2 disease.
Methods We assessed patients treated for stage 1 HAT caused by Trypanosoma brucei gambiense in the Republic of the Congo 
between April 2001 and April 2005. Patients with 0–10 cells/mm³ in CSF were classed as stage 1 and treated with pentamidine. 
Patients with CSF of > 10 cells/mm³ were classed as stage 2 and treated with either melarsoprol or eflornithine. We did a retrospective 
analysis of all patients treated after the September 2002 increase in threshold for classification of HAT disease stage 2, and who 
were eligible for at least 1 year of follow-up. Primary outcome was survival without death or relapse within 1 year of discharge. Risk 
factors for treatment failure, in particular CSF white cell count on diagnosis, were assessed.
Findings Between September 2002 to April 2004, 692 patients eligible for our analysis were treated with pentamidine. All were 
discharged alive. Relapse rate was 5% (n = 33). The only identified risk factor for relapse was a CSF white cell count of 6–10 cells/mm³ 
rather than 0–5 cells/mm³ (adjusted hazard ratio 3.27 (95% confidence interval, 1.52–7.01); P = 0.002).
Conclusion A threshold of 5 white cells/mm³ in CSF is safer than 10 cells/mm³ to determine stage 2 HAT and reduce risk of relapse.
Bulletin of the World Health Organization 2006;84:777-782.
Voir page 781 le résumé en français. En la página 781 figura un resumen en español.
Introduction
Human African trypanosomiasis (sleepi
ing sickness) caused by the parasite 
Trypanosoma brucei gambiense is eni
demic in the Republic of the Congo. 
The disease is transmitted by the tsetse 
fly (Glossina genus) and manifests itself 
in two stages. The early stage (stage 1) 
occurs shortly after initial infection and 
can present as a haemolymphatic illness 
with fever, headaches, lymphadenopathy, 
and organomegaly. The late stage (stage 
2) presents several months or even years 
after infection and is characterized by 
central nervous system involvement. The 
disease is fatal if untreated.
The early and late stages of sleeping 
sickness are differentiated by visualizai
tion of the parasite in cerebrospinal fluid 
(CSF) or the proxy indicator of white cell 
count in CSF. Treatment varies accordi
ing to stage. Pentamidine is currently the 
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standard recommended treatment for 
the early stage of the disease. This drug 
is a waterisoluble compound given at a 
dose of 4 mg/kg once daily for 7 days 
either intramuscularly or by slow intrai
venous injection. Maximum plasma coni
centrations are attained within 1 hour of 
an intramuscular injection, but the drug 
is largely bound to plasma proteins and 
has a longilasting action with a slow rate 
of excretion.1 Importantly, only very low 
concentrations of the drug are achieved 
in CSF, making it unsuitable for use in 
confirmed stage 2 cases.2
Médecins Sans Frontières (MSF) 
has run three trypanosomiasis interveni
tion programmes in conjunction with 
the Republic of the Congo National 
Programme (the Programme National de 
lutte contre la Trypanosomiase Humaine 
Africaine (PNLTHA)) in Gamboma 
(from April 2001), Nkayi (September 
2002), and Mossaka (July 2003) in the 
Plateaux, Bouenza, and Cuvette regions, 
respectively. The programmes ended in 
April 2005.
In September 2002, the MSF proi
grammes, in accordance with a recomi
mendation by the PNLTHA, increased 
the threshold separating stage 1 and 2 
cases from 5 cells/mm³ to 10 cells/mm³. 
This change was accompanied by a fori
mal revision to the PNLTHA protocol 
in 2003. We did a retrospective analysis 
in a cohort of stage 1 patients treated for 
human African trypanosomiasis caused 
by T.b. gambiense in the Republic of the 
Congo. We aimed to assess whether the 
use of a higher CSF white cell count 
threshold increased the risk of relapse.
Methods
Patients were originally enrolled through 
passive case detection at fixed sites, as 
well as by active case detection by mobile 
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teams systematically screening villages. 
The national protocol of the PNLTHA 
guided diagnosis and treatment.
Diagnosis (Fig. 1) involved screeni
ing (card agglutination trypanosomiasis 
test (CATT) with whole blood), confiri
mation (visualization of the parasite in 
blood or lymph, or a positive result with 
CATT dilution of 1 in 8), and staging 
(parasite found in CSF or CSF white cell 
count).
We analysed risk factors for treati
ment failure during the first year of 
followiup using Cox proportional 
hazards regression. Patients were ini
cluded in the analysis if they had a stage 1 
diagnosis, were treated with pentamidine 
(4mg/kg by intramuscular (IM) injeci
tion once daily for 7 days), admitted 
on or after September 2002 (the month 
when the stage 1 to stage 2 white cell 
count threshold was raised), and eligible 
for 1 year of follow up. Patients were 
excluded if they had not attended at 
least one followiup visit or if baseline 
variables such as age, sex, parasitological 
findings and treatment outcome were not 
in their records.
We restricted our analysis to the 
first year of followiup, since followiup 
rates were unacceptably low for longer 
periods. We took any visit from month 
10 (day 304) to month 14 (day 425) after 
discharge as the 1iyear followiup visit. 
We defined failure as death attributable 
to any cause after discharge, recurrence 
of parasites in any body fluid, CSF white 
cell count > 50 cells/mm³ and at least 
doubled from the previous measurement, 
or white cell count 11–49 cells/mm³ 
with either a significant increase from 
the previous measurement or with sympi
toms suggestive of sleeping sickness.3–5
Potential risk factors (treatment ceni
tre, sex, age, screening mode, technique 
on which parasitological confirmation 
was based (i.e. visualization of parasite or 
serological alone), CSF white cell count) 
and confounders (period during which 
the patient was admitted) were entered 
in the multivariate model if associated 
with the outcome at the P < 0.20 level in 
a univariate analysis. We forced semester 
of admission into the final model since 
pentamidine relapse rates varied over the 
duration of the project (data not shown). 
We also tested for interactions between 
covariates and verified the proportionali
ity assumption.
Data were entered at programme 
locations into either an Excel database 
(Gamboma) or YoTryps (Nkayi and 
Mossaka), a Microsoft Accessibased 
software designed for human African 
trypanosomiasis programmes. Data were 
analysed with Stata version 8.0 (Stata 
Corp, College Station, Texas, USA).
Ethical approval
The study was a retrospective analysis on 
Médecins Sans Frontières’ operational 
medical work in the Republic of the 
Congo. Approval for data exportation, 
analysis and reporting was obtained from 
the PNLTHA of the Republic of the 
Congo. The data sets extracted and used 
for analysis were anonymized through 
removal of all patients’ names, separation 
into a new dataset, and analysis by a statistii
cian unconnected with the programmes.
Results
Between April 2001 and March 2005, 
1986 patients were diagnosed with 
primary stage 1 human African trypanoi
somiasis. Criteria for selection of the 
cohort retained for analysis is shown in 
Fig. 2. Of 692 patients discharged alive 
after treatment with pentamidine, 454 
(66%) and 371 (54%) attended followi
up at 6 months (± 2 months) and one 
year (± 2 months), respectively. Overall, 
652 patients (94%) attended at least one 
Fig. 1. Scheme showing the various steps used in diagnosis of study cases
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a  CATT = Card agglutination trypanosomiasis test (whole blood).
b  Gland puncture = lymph node (aspiration).
c  Haematocrit centrifugation test is also known as the Woo test.
d  Serological cases are those that are CATT 1/8 positive but have no trypanosomes detected in cerebrospinal fluid.
e  CSF = cerebrospinal fluid.
followiup visit and were included in the 
multivariate analysis. Table 1 shows their 
baseline characteristics.
Patients not attending at 1iyear 
followiup differed significantly from 
those who did attend in the semester of 
admission: 159 of 228 patients (70%) 
admitted in September 2002 to March 
2003 were seen, compared with 212 of 
424 (50%) later; P < 0.001. Groups did 
not differ with respect to any other basei
line characteristics.
There were 33 treatment failures 
(5% of 652 eligible for analysis). Age, 
sex, mode of screening and technique of 
diagnosis (parasitological or serological) 
did not affect risk of failure (Table 1). 
The proportion of failures was higher 
in patients with a white cell count of 
6–10 cells/mm³ than in those with white 
cell count of 0–5 cells/mm³ (10 of 84 
(12%) versus 23 of 568 (4%) eligible 
for analysis). Patients with a white cell 
count of 6–10 cells/mm³ had a similar 
median duration of followiup to those 
with white cell count of 0–5 cells/mm³ 
(316 versus 338 days; P = 0.880). Among 
the 41 defaulters, 18 diagnoses (44%) 
were serological in the 6–10 cells/mm³ 
group compared with 165 of 240 (69%) 
in the 0–5 cells/mm³ group (P = 0.004); 
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defaulters in the two exposure groups 
were otherwise similar.
Patients treated with pentamidine 
with a raised white cell count (6–10 
cells/mm³) had a significantly higher risk 
of failure (adjusted hazard ratio 3.27; 
P = 0.002) than did those with a white 
cell count of 0–5 cells/mm³ (Table 1). 
The association remained significant 
when stratified by treatment centre: 
2.75 (95% confidence interval (CI), 
0.99–7.67) in Nkayi and 4.48 (95% CI: 
1.29–15.52) in Mossaka.
Discussion
Our results show that the risk of treati
ment failure in patients with a CSF white 
cell count of 6–10 cells/mm³ is three 
times higher than in those with a count 
of 0–5 cells/mm³. This difference may 
be because some of these patients had 
late stage or stage 2 disease for which 
pentamidine treatment is ineffective.
Attempts have been made to use 
pentamidine to treat patients with a 
mild elevation of CSF white cell count.6 
Doua et al.7 in Côte d’Ivoire, for example, 
showed that pentamidine could be effeci
tive in “intermediate” cases with a CSF 
white cell count between 6 cells/mm³ and 
20 cells/mm³. However, Lejon et al.8 in 
Uganda noted a higher risk of relapse for 
these patients treated with pentamidine8 
and went on to recommend a value of 10 
cells/mm³ as a more appropriate cut off. 
Ruiz et al.9 indeed found that a CSF white 
cell count of 6–10 cells/mm³ was not 
associated with a higher risk of relapse in 
patients treated with pentamidine.9 Our 
results somewhat contradict outcomes 
from these studies and indicate that a 
lower threshold of 5 cells/mm³ may be 
advisable in the Republic of the Congo.
A CSF white cell count cutioff of 
10 cells/mm³ to differentiate stage 1 
and 2 cases is a feature of the national 
diagnostic protocol of the PNLTHA. 
Many protocols use a cutioff point of 
5 cells/mm³. The reason for adopting a 
high threshold is because melarsoprol, 
which is highly toxic, was initially used 
for the treatment of stage 2 cases. This 
higher threshold seems justified in view 
of the fact that if the lower threshold 
of 5 cells/mm³ had been used, an addii
tional 84 patients (in the analysed group) 
would have been treated with potentially 
toxic stage 2 medication. Since about 
5% of all patients treated with melari
soprol die from severe adverse events, 
we calculate that treatment of these 84 
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619 admitted before September 2002
(when CSFb white cell count threshold
for stage 1 treatment was changed)
499 discharged in the last year of the intervention
(insufficient follow-up time)
175 with one or more missing variables
1 died during admission
40 did not attend a control visit during the first year
a  HAT = human African trypanosomiasis.
b  CSF = cerebrospinal fluid.
extra patients with melarsoprol would 
have resulted in 4 additional deaths to 
prevent 10 relapses.
However, we feel that where an alteri
native to melarsoprol, such as eflornithine 
is available, use of a higher threshold is 
not justified.10 In our programme in the 
Republic of the Congo we also found a 
relatively low case fatality rate of 1.7% 
(n = 5) among 288 patients treated with 
eflornithine. Furthermore, the idea that 
one can have a positive risk–benefit with 
a higher CSF white cell count is based 
on the assumption that all patients can 
be followed up and any extra relapses 
can be retreated. In our programme, dei
spite additional resources not normally 
available to the PNLTHA, only 54% of 
patients attended followiup at 1 year. 
In areas where good followiup rates can 
not be guaranteed, additional deaths in 
the community may occur in patients 
who relapse or who are lost or unable to 
attend followiup.
Overall, the treatment failure rate 
(5%) in our programme was accepti
able and similar to levels noted in other 
studies.6,11,12 A high proportion (62%) of 
patients entered in the analysis of relapse 
risk were diagnosed serologically, in the 
absence of visualized parasites. This low 
rate of parasite detection may be related 
to poor laboratory performance. As such, 
the treatment of serological cases with a 
CATT end titre > 1/8 has been proposed 
as a control strategy in areas with a high 
prevalence of sleeping sickness.13 Howi
ever, many serological cases may not be 
true cases at all and positive results may 
be the result of, for example, presumed 
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cases having been treated several years 
ago. There is evidence of immunity foli
lowing T.b. gambiense infection and it 
is also known that results of the CATT 
may remain positive for some time.14,15 
Furthermore, the positive predictive 
value of the CATT dilutions is uni
known and may vary over the length of 
a control programme. Perhaps a higher 
threshold of even 1/16 or 1/32 should 
be considered especially when the overall 
prevalence of the disease is moderate 
to low.
Our results should be interpreted 
with some caution since they are dei
rived from a retrospective analysis, and 
are not from a randomized study but 
from a fieldibased medical intervention. 
Additionally, our data were insufficient 
Table 1. Baseline characteristics of patients and risk factors for treatment failure within first year after discharge in stage 1 
patients treated with pentamidine




Relapses Crude hazard ratio 
(95%CIb)
Adjusted hazard ratioa 
(95%CI) 
Treatment centre
Nkayi 457 (70%) 23 1.00 –
Mossaka 195 (30%) 10 1.15 (0.54–2.42) –
Semester of admission
September 2002 to March 2003 228 (35%) 13 1.00 1.00
April to September 2003 217 (33%) 13 1.04 (0.48–2.27) 0.86 (0.39–1.91)
October 2003 to March 2004 207 (32%) 7 0.66 (0.26–1.65) 0.55 (0.22–1.40)
Sex
Male 351 (54%) 19 1.00 –
Female 301 (46%) 14 0.90 (0.45–1.77) –
Age
> 15 years 504 (77%) 23 1.00 –
< 15 years 148 (23%) 10 1.47 (0.70–3.09) –
Mode of screening
Active 490 (75%) 26 1.00 –
Passive 162 (25%) 7 0.69 (0.30–1.60) –
Technique on which diagnosis and 
staging was based
Direct gland puncture 157 (24%) 9 1.00 –
Centrifugation (Woo or QBCc) 98 (15%) 7 1.11 (0.41–3.00) –
CATT positive at dilution 1/8 or higher 396 (61%) 17 0.83 (0.37–1.87) –
White cell count in CSFd
0–5 cells/ mm3 568 (87%) 23 1.00 1.00
6–10 cells/ mm3 84 (13%) 10 3.05 (1.45–6.40) 3.27 (1.52–7.01)
a  Adjusted hazard ratios based on Cox regression model with P = 0.030 (goodness of fit).
b  CI = confidence interval.
c  QBC = quantitative buffy coat.
d  CSF = cerebrospinal fluid.
to analyse outcomes beyond 1 year of 
followiup; patients can relapse up to 3 
years after initial treatment.11
Conclusion
Overall, pentamidine was safe and well 
tolerated. However, a CSF white cell 
count of 10 cells/mm³ as the threshold 
between stage 1 and 2 cases seems to be 
associated with a higher risk of relapse. 
Therefore, we recommended that stage 
1 should be defined by a CSF white cell 
count of 0–5 cells/mm³ (with absence 
of trypanosomes in the CSF) and that a 
count of 6 cells/mm³ and greater should 
be treated as a stage 2 case, especially if 
the alternative stage 2 drug eflornithine 
is available and can be safely adminisi
tered. In view of a higher risk of relapse, 
a higher threshold should be used in 
the context where good followiup is 
possible. Surveillance of treated cases is 
important to monitor development of 
possible resistance to pentamidine.  O
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Résumé
Résultats du traitement et facteurs de risque de rechute chez les personnes atteintes de trypanosomiase 
africaine humaine (TAH) à un stade peu avancé en République du Congo
Resumen
Resultados terapéuticos y factores de riesgo de recaída en pacientes con tripanosomiasis africana 
humana (TAH) en fase inicial en la República del Congo
Objetivo En 2002–2003, la República del Congo aumentó el 
umbral de separación de los casos de fase 1 y 2 de tripanosomiasis 
africana humana (TAH) de un recuento de leucocitos en líquido 
cefalorraquídeo (LCR) de 5 células/mm3 a 10 células/mm³. 
Decidimos determinar si ese mayor umbral, de 10 células/mm³, es 
un indicador seguro de la fase 2 de la enfermedad.
Métodos Evaluamos a pacientes tratados contra la TAH por 
Tripanosoma brucei gambiense en fase 1 en la República del 
Congo entre abril de 2001 y abril de 2005. Los pacientes con 0–10 
células/mm³ en LCR se clasificaron como fase 1 y fueron tratados 
con pentamidina. Los pacientes con más de 10 células/mm³ en LCR 
se clasificaron como fase 2 y fueron tratados con melarsoprol o 
eflornitina. Hicimos un análisis retrospectivo de todos los pacientes 
tratados después de aumentar el umbral de definición de la fase 2, 
en septiembre de 2002,  y considerados aptos para un seguimiento 
de al menos un año. Como variable principal de valoración se 
empleó la supervivencia sin defunción o recaída durante el primer 
año tras el alta. Se evaluaron los factores de riesgo de fracaso 
terapéutico, en particular el recuento de leucocitos en LCR en el 
momento del diagnóstico.
Resultados Entre septiembre de 2002 y abril de 2004, 692 
pacientes aptos para nuestro análisis fueron tratados con 
pentamidina. Todos sobrevivieron y recibieron el alta. La tasa de 
recaídas fue del 5% (n=33).  El único factor de riesgo conocido fue 
un recuento de leucocitos en LCR de 6-10 células/mm³ en lugar de 
0-5 células/mm3 (razón de riesgos instantáneos ajustada = 3,27 
(intervalo de confianza del 95% = 1,52–7,01); P = 0,002).
Conclusiones La cifra de 5 leucocitos/mm³ en el LCR es más 
segura que 10 leucocitos/mm³ como umbral para determinar la 
fase 2 de la TAH y reducir el riesgo de recaída.
صخلم
ةركابلا ةلحرلما ضىرم ىدل سكنلا رطخ لماوعو ةجلاعلما لئاصح
وغنوكلا ةيروهمج في يقيرفلأا يشربلا تايبقثلما ءاد نم
 لصفلا  ةبتع  نم  وغنوكلا  ةيروهمج تداز  2003i2002  ْيَماع  في  :فدهلا
 يشربلا تايبقثلما ءاد تلااح صيخشت في ةيناثلا ةلحرلماو لىولأا ةلحرلما ينب
 نأ دعب يعاخنلا لئاسلا نم بعكم ترميلم لكل ايلاخ 10 حبصتل يقيرفلأا
 ةدايزلا هذه تناك اذإ مايف ميـيقت انفدهو .بعكم ترميلم لكل ايلاخ 5 تناك
.ءادلا اذه نم ةيناثلا ةلحرملل ةنومألما تاشرؤلما نم
 ءاد  نم  لىولأا  ةلحرلماب  مهتباصلإ  اوجلوع  ضىرلم  ًمايـيقت  انيرجأ  :ةقيرطلا
 ةيروهمج في ةيبماغلا ةيسوبرلا تايبقثلما نع مجانلا يقيرفلأا يشربلا تايبقثلما
 فِّنُص دقو .2005 ليربإ/ناسينو 2001 ليربإ/ناسين ينب ةرـتفلا في وغنوكلا
 يعاخنلا لئاسلا نم بعكم ترميلم لكل ايلاخ 10i0 مهيدل ناك نيذلا ضىرلما
 ددع داز نيذلا ضىرلما فِّنُص مايف ،نيديماتنبلاب وجلوعو لىولأا ةلحرلما نمض
 ةلحرلما في بعكم ترميلم لكل ايلاخ 10 نع مهيدل يعاخنلا لئاسلا في ايلاخلا
 لكل ًايداعتسا ًلايلحت انيرجأو .ينثينرولفيلإاب وأ لوبرسرلايلماب اوجلوعو ةيناثلا
 ءادب ضىرلما فينصت ةبتع ةدايز تلت يتلا ةرـتفلا في اوجلوع نيذلا ضىرلما
 برمتبس/لوليأ  رهش  دعب  ،ةيناثلا  ةلحرلما  نمض  يقيرفلأا  يشربلا  تايبقثلما
 ةيلولأا ةليصحلا تناك دقو .ةنس ةدلم ةعباتملل ينلهؤم اوناك نممو ،2002
 جيرختلا لىع ةنس رورم دعب سكن ثودحو مدعو ةايحلا ديق لىع ءاقبلا يه
 ددع رثأ  ماَّيسلاو ،ةجلاعلما  لشفل  رطخلا  لماوع  انمَّيق  ماك ،ىفشتسلما  نم
.صيخشتلا لىع يعاخنلا لئاسلا في ءاضيبلا )تايركلا( ايلاخلا
 ةجلاعملل  ةيليلحتلا  ةساردلل  ًلاهؤم  ًاضيرم  692  جلوع  :تادوجولما
 دقو .2004 ليربإ/ناسينو 2002 برمتبس/لوليأ ينب ةرـتفلا في نيديماتنبلاب
Objectif Dans les années 2002-2003, les responsables sanitaires 
de la République du Congo ont fait passer de 5 leucocytes/mm³ 
à 10 leucocytes/mm³ le seuil de séparation des  stades 1 et 2 de 
la trypanosomiase africaine humaine (TAH) d’après la numération 
leucocytaire dans le liquide céphalorachidien. On s’est efforcé 
d’évaluer la sécurité du tri effectué à partir du seuil augmenté de 10 
leucocytes/mm³ en tant qu’indicateur du stade 2 de la maladie.
Méthodes On a évalué des patients traités pour une TAH au 
stade 1 due à Trypanosoma brucei gambiense en République 
du Congo entre avril en 2001 et avril 2005. Les patients dont 
la numération leucocytaire dans le liquide céphalorachidien se 
situait entre 0 et 10 leucocytes/mm³ ont été classés «stade 1» 
et traités par la pentamidine. Ceux dont la numération était > 
10 leucocytes/mm³ ont été classés «stade 2» et traités par du 
mélarsoprol ou de l’éflornithine. Une étude rétrospective a été 
réalisée sur l’ensemble des patients traités après l’augmentation du 
seuil de classification de la TAH en stade 2 effectuée en septembre 
2002 et répondant aux critères d’inclusion dans un suivi d’un an au 
moins. Les deux principaux résultats du traitement pris en compte 
étaient la survie sans décès ou la rechute dans l’année suivant la 
sortie de l’établissement de soins.  Les facteurs de risque d’échec 
thérapeutique, notamment la numération leucocytaire dans le 
liquide céphalorachidien, ont été évalués.
Résultats Entre septembre 2002 et avril 2004, 692 patients 
remplissant les critères d’inclusion dans l’analyse ont été traités 
par la pentamidine. Tous ont quitté l’établissement de soins vivants. 
Le taux de rechute était de 5 % (n = 33). Le seul facteur de risque 
de rechute identifié était une numération leucocytaire située entre 
6 et 10 leucocytes/mm³, par comparaison avec une valeur de 
10 leucocytes/mm³ (rapport de risque ajusté 3,27; intervalle de 
confiance à 95 % : 1,52 - 7,01; p = 0,002).
Conclusion Le seuil de 5 leucocytes/mm³ dans le liquide 
céphalorachidien est plus sûr que celui de 10 leucocytes/mm³ pour 
définir une TAH au stade 2 et réduire le risque de rechute.
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 )ًاضيرم 33( %5 سكنلا لدعم ناكو ،ًءايحأ ىفشتسلما نم مهعيمج جرخت
 حوارـتي  يذلا  ضيبلا  تايركلا  ددع  وه  سكنلل  ديحولا  رطخلا  لماع  ناكو
 ذإ .بعكم ترميلم/ايلاخ 0i5 نم ًلادب بعكم ترميلم لكل ايلاخ 10i6 ينب
 1.52 ينب حوارـتت ميقل ،95% ةقث ةلصافب( 3.27 ح َّحَصُلما رطخلا لدعم غلب
.)0.002 لماتحا ةميقبو ،7.01و
 ًانامأ ثركأ يعاخنلا لئاسلا نم بعكم ترميلم لكل ايلاخ 5 ةبتع نإ :جاتنتسلاا
 ةلحرلما صيخشت في يعاخنلا لئاسلا نم بعكم ترميلم لكل ايلاخ 10 نم
 رطخ نم صقنتس ةبتعلا هذهو ،يقيرفلأا يشربلا تايبقثلما ءاد نم ةيناثلا
.سكنلا
